KAREN GOING: Open Payments
NPI 1588962369 · WASHINGTON, DC. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,449 in 65 payments from 15 companies in 2025. Trend: 2023 $211 · 2024 $836 · 2025 $1,449
Food & beverage: $1,449
| Company | Payments | Amount |
|---|---|---|
| GlaxoSmithKline, LLC. | 13 | $251 |
| Novo Nordisk Inc | 10 | $207 |
| Lilly USA, LLC | 6 | $204 |
| E.R. Squibb & Sons, L.L.C. | 5 | $177 |
| Lundbeck LLC | 5 | $145 |
| Bayer Healthcare Pharmaceuticals Inc. | 7 | $133 |
| Phathom Pharmaceuticals, Inc. | 6 | $57 |
| Exact Sciences Corporation | 2 | $54 |
| AstraZeneca Pharmaceuticals LP | 3 | $53 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 2 | $39 |
Products named: COBENFY, REXULTI, SHINGRIX, Kerendia, MOUNJARO, TRELEGY ELLIPTA, Ozempic, ZEPBOUND.
Industry payments across DC — which companies pay providers there.
